Deaths from heart valve disease rising among U.S. adults ages 65 and older

Among U.S. adults aged 65 and older, valvular heart disease mortality rose nearly 5% from 2018 to 2023, reaching 109.2 deaths per 100,000 after a decline from 123.2 in 1999. Researchers project rates will remain around 109.2 per 100,000 through 2040, with higher rates among men, non-Hispanic white adults, people aged 85 and older, and nonmetropolitan residents. The findings are preliminary and based on death-certificate data, which may contain coding inaccuracies and cannot establish causality.

Analysis

This is not a clean demand signal for valve-device makers. Mortality is a lagging outcome, not a measure of diagnosed cases, eligible patients, procedures, or reimbursement; the study also cannot separate pandemic-era care disruption from underlying disease trends. The commercially relevant mechanism is whether excess mortality reflects missed diagnosis and referral bottlenecks that can be converted into more treated patients. Rural access and very-old-age care suggest capacity and pathway constraints, not automatically incremental procedure volume.

If follow-up data show more patients identified and treated, structural heart franchises at Edwards Lifesciences, Medtronic, and Abbott could benefit; echocardiography and hospital service capacity may be complementary beneficiaries. But the abstract does not establish that link, and higher mortality could instead reflect patients too frail or late-stage for intervention. It therefore does not support a near-term earnings or valuation revision by itself.

Near term, expect limited durable market impact: the findings are preliminary and mortality data are backward-looking. Over 1–3 months, peer review and AHA discussion may clarify whether the post-2018 pattern persists after accounting for pandemic effects. Over 6–18 months, watch for evidence that screening, referral, and treatment rates are improving—especially outside metropolitan centers. Contrarian point: a stable projected death rate through 2040 is not a forecast of rising device demand; improved access and treatment could reduce mortality without a proportional increase in procedure economics, while demographic aging could raise deaths absent any change in per-patient care.

Key Decisions for Investors

• No trade on this abstract alone. Avoid treating the mortality trend as a direct catalyst for Edwards Lifesciences, Medtronic, or Abbott without corroboration in procedure volumes, patient eligibility, or company guidance.
• Add structural-heart names to a watch list; revisit after the full peer-reviewed paper and AHA meeting. Verify age-adjusted diagnosis and intervention rates, pandemic-period sensitivity, and whether nonmetropolitan access is improving.
• For a 1–3 month catalyst check, monitor earnings commentary and clinical or registry data for TAVR and other valve procedures. A sustained rise in eligible-patient referrals and procedures would strengthen the demand thesis; flat volumes despite elevated mortality would falsify the access-to-revenue link.
• Treat the rural-access angle as a capacity and execution risk: monitor hospital staffing, referral pathways, and treatment-site expansion before assuming unmet need converts into revenue.